PDF(Pubmed)
Abstract：
UNASSIGNED: The utility of hepatitis B immunoglobulin (HBIg) in hepatitis D virus (HDV)-reactivation prophylaxis remains contentious. This study compared liver transplant (LT) patients based on whether they received perioperative HBIg to assess its protective effect against HDV reactivation.
UNASSIGNED: Fifty-seven recipients with hepatitis B virus (HBV) and HBV/HDV, who were at least 1 year posttransplantation as of January 1, 2021, were enrolled in this single-center study. Tests for hepatitis B surface antigen (HBsAg), anti-HDV antibody, and quantitative reverse transcription polymerase chain reaction for HBV DNA and HDV RNA were performed. Interviews were conducted to assess compliance with the nucleos(t) ide analogue (NA) regimen and to document preoperative HBV/HDV status. Liver function tests were also carried out. The nonparametric Mann-Whitney U-test was utilized to determine statistical significance, with P<0.05 considered significant. Data analysis was conducted using GraphPad Prism software.
UNASSIGNED: The prevalence of HDV RNA, HBV DNA, HBsAg, and anti-HDV positivity in the HBIg group (n=23) was 4.3% (n=1), 17.4% (n=4), 8.7% (n=2), and 95.7% (n=22), respectively. In the non-HBIg group (n=34), these rates were 5.9% (n=2), 8.8% (n=3), 11.8% (n=4), and 97.1% (n=33), respectively. Interviews revealed that all reactivations occurred in patients who were noncompliant with their NA regimen. Eleven of the 13 patients initially reported to be monoinfected with HBV pretransplantation were anti-HDV-positive.
UNASSIGNED: No HDV replication occurred in either group due to spontaneous reactivation. High-efficacy NAs appear to be effective in sustaining HDV suppression post-LT. Most recrudescent cases of chronic hepatitis D are mild and self-limiting, typically resolving after 1-2 years of replication, as evidenced by liver function tests.
UNASSIGNED: Fifty-seven recipients with hepatitis B virus (HBV) and HBV/HDV, who were at least 1 year posttransplantation as of January 1, 2021, were enrolled in this single-center study. Tests for hepatitis B surface antigen (HBsAg), anti-HDV antibody, and quantitative reverse transcription polymerase chain reaction for HBV DNA and HDV RNA were performed. Interviews were conducted to assess compliance with the nucleos(t) ide analogue (NA) regimen and to document preoperative HBV/HDV status. Liver function tests were also carried out. The nonparametric Mann-Whitney U-test was utilized to determine statistical significance, with P<0.05 considered significant. Data analysis was conducted using GraphPad Prism software.
UNASSIGNED: The prevalence of HDV RNA, HBV DNA, HBsAg, and anti-HDV positivity in the HBIg group (n=23) was 4.3% (n=1), 17.4% (n=4), 8.7% (n=2), and 95.7% (n=22), respectively. In the non-HBIg group (n=34), these rates were 5.9% (n=2), 8.8% (n=3), 11.8% (n=4), and 97.1% (n=33), respectively. Interviews revealed that all reactivations occurred in patients who were noncompliant with their NA regimen. Eleven of the 13 patients initially reported to be monoinfected with HBV pretransplantation were anti-HDV-positive.
UNASSIGNED: No HDV replication occurred in either group due to spontaneous reactivation. High-efficacy NAs appear to be effective in sustaining HDV suppression post-LT. Most recrudescent cases of chronic hepatitis D are mild and self-limiting, typically resolving after 1-2 years of replication, as evidenced by liver function tests.
摘要：
■乙型肝炎免疫球蛋白（HBIg）在丁型肝炎病毒（HDV）再激活预防中的应用仍然存在争议。这项研究比较了肝移植（LT）患者是否接受围手术期HBIg，以评估其对HDV再激活的保护作用。
■57位乙型肝炎病毒（HBV）和HBV/HDV患者，自2021年1月1日起移植后至少1年的患者被纳入这项单中心研究.乙型肝炎表面抗原（HBsAg）的测试，抗HDV抗体，并对HBVDNA和HDVRNA进行定量逆转录聚合酶链反应。进行访谈以评估对核苷（t）ide类似物（NA）方案的依从性，并记录术前HBV/HDV状态。还进行了肝功能测试。非参数Mann-WhitneyU检验用于确定统计显著性，P<0.05被认为是显著的。使用GraphPadPrism软件进行数据分析。
■HDVRNA的患病率，HBVDNA，HBsAg,HBIg组（n=23）的抗HDV阳性率为4.3％（n=1），17.4%(n=4)，8.7%(n=2)，和95.7％（n=22），分别。在非HBIg组中（n=34），这些比率为5.9%(n=2)，8.8%(n=3)，11.8%(n=4)，和97.1％（n=33），分别。访谈显示，所有激活均发生在不符合NA方案的患者中。最初报告为移植前HBV单感染的13例患者中有11例抗HDV阳性。
■由于自发再激活，两组中均未发生HDV复制。高效NAs似乎可有效维持LT后的HDV抑制。大多数慢性丁型肝炎的复发病例是轻度和自限性，通常在复制1-2年后解析，肝功能测试证明了这一点。
■57位乙型肝炎病毒（HBV）和HBV/HDV患者，自2021年1月1日起移植后至少1年的患者被纳入这项单中心研究.乙型肝炎表面抗原（HBsAg）的测试，抗HDV抗体，并对HBVDNA和HDVRNA进行定量逆转录聚合酶链反应。进行访谈以评估对核苷（t）ide类似物（NA）方案的依从性，并记录术前HBV/HDV状态。还进行了肝功能测试。非参数Mann-WhitneyU检验用于确定统计显著性，P<0.05被认为是显著的。使用GraphPadPrism软件进行数据分析。
■HDVRNA的患病率，HBVDNA，HBsAg,HBIg组（n=23）的抗HDV阳性率为4.3％（n=1），17.4%(n=4)，8.7%(n=2)，和95.7％（n=22），分别。在非HBIg组中（n=34），这些比率为5.9%(n=2)，8.8%(n=3)，11.8%(n=4)，和97.1％（n=33），分别。访谈显示，所有激活均发生在不符合NA方案的患者中。最初报告为移植前HBV单感染的13例患者中有11例抗HDV阳性。
■由于自发再激活，两组中均未发生HDV复制。高效NAs似乎可有效维持LT后的HDV抑制。大多数慢性丁型肝炎的复发病例是轻度和自限性，通常在复制1-2年后解析，肝功能测试证明了这一点。
